NZ304906A - Use of fumagillol or a fumagillol ester and an optionally saturated alkylcarboxylic or alkyldicarboxylic acid to fight intestinal infections - Google Patents

Use of fumagillol or a fumagillol ester and an optionally saturated alkylcarboxylic or alkyldicarboxylic acid to fight intestinal infections

Info

Publication number
NZ304906A
NZ304906A NZ304906A NZ30490696A NZ304906A NZ 304906 A NZ304906 A NZ 304906A NZ 304906 A NZ304906 A NZ 304906A NZ 30490696 A NZ30490696 A NZ 30490696A NZ 304906 A NZ304906 A NZ 304906A
Authority
NZ
New Zealand
Prior art keywords
fumagillol
fight
ester
intestinal infections
optionally saturated
Prior art date
Application number
NZ304906A
Other languages
English (en)
Inventor
Jean-Michel Molina
Francis Derouin
Original Assignee
Sanofi Sa
Assist Publ Hopitaux De Paris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa, Assist Publ Hopitaux De Paris filed Critical Sanofi Sa
Publication of NZ304906A publication Critical patent/NZ304906A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/10Anthelmintics
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NZ304906A 1995-03-27 1996-03-26 Use of fumagillol or a fumagillol ester and an optionally saturated alkylcarboxylic or alkyldicarboxylic acid to fight intestinal infections NZ304906A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9503549 1995-03-27
PCT/FR1996/000448 WO1996030010A2 (fr) 1995-03-27 1996-03-26 Utilisation du fumagillol et ses derives pour preparer les medicaments destines a combattre les infections intestinales

Publications (1)

Publication Number Publication Date
NZ304906A true NZ304906A (en) 1999-06-29

Family

ID=9477436

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ304906A NZ304906A (en) 1995-03-27 1996-03-26 Use of fumagillol or a fumagillol ester and an optionally saturated alkylcarboxylic or alkyldicarboxylic acid to fight intestinal infections

Country Status (25)

Country Link
US (1) US5900431A (Direct)
EP (1) EP0817626B1 (Direct)
JP (1) JP3260378B2 (Direct)
KR (1) KR100286920B1 (Direct)
CN (1) CN1072485C (Direct)
AP (1) AP646A (Direct)
AT (1) ATE172641T1 (Direct)
AU (1) AU706161B2 (Direct)
CA (1) CA2216623C (Direct)
CZ (1) CZ286821B6 (Direct)
DE (1) DE69600879T2 (Direct)
DK (1) DK0817626T3 (Direct)
EA (1) EA000150B1 (Direct)
ES (1) ES2128846T3 (Direct)
FR (1) FR06C0014I2 (Direct)
HU (1) HU224028B1 (Direct)
IS (1) IS2048B (Direct)
NO (1) NO315968B1 (Direct)
NZ (1) NZ304906A (Direct)
OA (1) OA10515A (Direct)
PL (1) PL183378B1 (Direct)
SK (1) SK283883B6 (Direct)
TR (1) TR199701048T1 (Direct)
UA (1) UA41446C2 (Direct)
WO (1) WO1996030010A2 (Direct)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK283883B6 (sk) * 1995-03-27 2004-04-06 Sanofi-Synthelabo Použitie fumagillolu a jeho derivátov na prípravu liekov proti intestinálnym chorobám a farmaceutický prostriedok
EP0799616A1 (en) * 1996-04-01 1997-10-08 Takeda Chemical Industries, Ltd. Oral composition comprising a fumagillol derivative
AU2811400A (en) 1999-02-26 2000-09-14 Sanofi-Synthelabo Stable formulation containing fumagillin
JP3265394B1 (ja) * 2001-03-14 2002-03-11 泰三 矢野 アクリル系樹脂手袋
DE10341887A1 (de) * 2003-09-09 2005-03-31 Leopold Kostal Gmbh & Co. Kg Elektrisches Schaltermodul
FR2886855B1 (fr) * 2005-06-08 2009-07-17 Agronomique Inst Nat Rech Utilisation de la fumagilline et de ses derives pour augmenter la biodisponibilite des lactones macrocyliques
MX2010005857A (es) * 2007-11-28 2010-11-22 Mersana Therapeutics Inc Conjugados de analogos de fumagillina biodegradables biocompatibles.
CA2731020A1 (en) * 2008-07-18 2010-01-21 Zafgen, Inc. Use of antiangiogenic fumagillins in the treatment of obesity
WO2010065877A2 (en) 2008-12-04 2010-06-10 Zafgen Corporation Methods of treating an overweight or obese subject
US8642650B2 (en) 2008-12-04 2014-02-04 Zafgen, Inc. Methods of treating an overweight or obese subject
WO2011044506A2 (en) 2009-10-09 2011-04-14 Zafgen Corporation Sulphone compounds and methods of making and using same
US8772333B2 (en) 2010-01-08 2014-07-08 Zafgen, Inc. Fumigillol type compounds and methods of making and using same
WO2011085198A1 (en) 2010-01-08 2011-07-14 Zafgen Corporation Metap-2 inhibitor for use in treating benign prostatic hypertrophy (bph)
WO2011127304A2 (en) 2010-04-07 2011-10-13 Zafgen Corporation Methods of treating an overweight subject
WO2012012642A1 (en) 2010-07-22 2012-01-26 Zafgen Corporation Tricyclic compounds and methds of making and using same
PH12013500934A1 (en) 2010-11-09 2022-10-24 Zafgen Inc Crystalline solids of a metap-2 inhibitor and methods of making and using same
CN103379905A (zh) 2010-11-29 2013-10-30 扎夫根股份有限公司 使用非每天施用的6-0-(4-二甲基氨基乙氧基)肉桂酰烟曲霉醇治疗肥胖症
CA2825408A1 (en) 2011-01-26 2012-08-02 Zafgen, Inc. Tetrazole compounds and methods of making and using same
US9328082B2 (en) 2011-03-08 2016-05-03 Zafgen, Inc. Oxaspiro[2.5]octane derivatives and analogs
AU2012253760B2 (en) 2011-05-06 2016-02-04 Zafgen, Inc. Tricyclic pyrazole sulfonamide compounds and methods of making and using same
JP6062423B2 (ja) 2011-05-06 2017-01-18 ザフゲン,インコーポレイテッド 部分飽和三環式化合物ならびにその製造および使用方法
JP5941981B2 (ja) 2011-05-06 2016-06-29 ザフゲン,インコーポレイテッド 三環式スルホンアミド化合物ならびにその製造および使用方法
EP2763671A2 (en) 2011-10-03 2014-08-13 Zafgen, Inc. Methods of treating age related disorders
KR20140112566A (ko) 2012-01-18 2014-09-23 자프겐 인크. 삼환식 설폰 화합물 그리고 그의 제조방법 및 그를 이용하는 방법
EP2804866B1 (en) 2012-01-18 2016-11-16 Zafgen, Inc. Tricyclic sulfonamide compounds and methods of making and using same
BR112014027808A2 (pt) 2012-05-07 2017-06-27 Zafgen Inc sal polimórfico do sal de oxalato de 6-o-(4-dimetilaminoetoxi) cinaroil fumagilol e métodos de produção e utilização do mesmo
MX2014013599A (es) 2012-05-08 2015-05-11 Zafgen Inc Tratamiento de la obesidad hipotalamica con inhibidores de metap2.
WO2013169860A1 (en) 2012-05-09 2013-11-14 Zafgen, Inc. Fumigillol type compounds and methods of making and using same
EA028367B1 (ru) 2012-11-05 2017-11-30 Зафджен, Инк. Способы лечения заболеваний печени
JP2015536981A (ja) 2012-11-05 2015-12-24 ザフゲン,インコーポレイテッド 三環式化合物ならびにその製造および使用方法
JP2015536983A (ja) 2012-11-05 2015-12-24 ザフゲン,インコーポレイテッド 肥満の治療及び抑制における三環式化合物の使用
BR112015023390A2 (pt) 2013-03-14 2017-07-18 Zafgen Inc métodos para tratar de doença renal e outros distúrbios
AR105671A1 (es) 2015-08-11 2017-10-25 Zafgen Inc Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso
CN106432255A (zh) 2015-08-11 2017-02-22 扎夫根公司 烟曲霉素醇螺环化合物和制备和使用其的方法
CN106591389B (zh) * 2015-10-15 2019-10-11 中国科学院微生物研究所 一种利用烟曲霉菌生产烟曲霉素的方法
CN105622593B (zh) * 2016-02-25 2018-06-26 中国农业科学院蜜蜂研究所 一种烟曲霉素的提取方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2791530A (en) * 1953-08-31 1957-05-07 Abbott Lab Stabilized fumagillin compositions
JPH0629278B2 (ja) * 1985-06-26 1994-04-20 藤沢薬品工業株式会社 オキサスピロオクタン化合物
US5135920A (en) * 1988-11-16 1992-08-04 Takeda Chemical Industries, Ltd. Angiostatic agents
JPH06504262A (ja) * 1990-07-27 1994-05-19 レブリゲン コーポレーション 脈管形成性の病気の処置用の新規な方法と組成物
US5328930A (en) * 1993-03-01 1994-07-12 Emory University Treatment of microsporidial and acanthamoeba keratoconjunctivitis with topical fumagillin
SK283883B6 (sk) * 1995-03-27 2004-04-06 Sanofi-Synthelabo Použitie fumagillolu a jeho derivátov na prípravu liekov proti intestinálnym chorobám a farmaceutický prostriedok
EP0799616A1 (en) * 1996-04-01 1997-10-08 Takeda Chemical Industries, Ltd. Oral composition comprising a fumagillol derivative
CA2210600A1 (en) * 1996-07-17 1998-01-17 Takashi Houkan Inhibitor of tumor metastasis or recurrence
AU3968597A (en) * 1996-08-02 1998-02-25 Children's Medical Center Corporation Method of regulating the female reproductive system through angiogenesis inhibitors

Also Published As

Publication number Publication date
DK0817626T3 (da) 1999-07-12
CA2216623C (en) 2005-05-31
AU706161B2 (en) 1999-06-10
NO315968B1 (no) 2003-11-24
TR199701048T1 (xx) 1998-01-21
CN1072485C (zh) 2001-10-10
DE69600879D1 (de) 1998-12-03
JPH11506421A (ja) 1999-06-08
US5900431A (en) 1999-05-04
SK130797A3 (en) 1998-03-04
CZ304997A3 (en) 1997-12-17
PL322470A1 (en) 1998-02-02
AP646A (en) 1998-04-27
UA41446C2 (uk) 2001-09-17
AU5278696A (en) 1996-10-16
FR06C0014I2 (Direct) 2006-12-29
NO974466D0 (no) 1997-09-26
ATE172641T1 (de) 1998-11-15
DE69600879T2 (de) 1999-06-02
JP3260378B2 (ja) 2002-02-25
EP0817626A2 (fr) 1998-01-14
CN1179715A (zh) 1998-04-22
IS2048B (is) 2005-09-15
OA10515A (fr) 2002-04-24
EP0817626B1 (fr) 1998-10-28
AP9701092A0 (en) 1997-10-31
HUP9801220A2 (hu) 1999-09-28
IS4557A (is) 1997-09-11
EA000150B1 (ru) 1998-10-29
CA2216623A1 (en) 1996-10-03
CZ286821B6 (en) 2000-07-12
SK283883B6 (sk) 2004-04-06
MX9707150A (es) 1998-07-31
ES2128846T3 (es) 1999-05-16
KR100286920B1 (ko) 2001-04-16
WO1996030010A3 (fr) 1996-11-28
HUP9801220A3 (en) 2001-10-29
NO974466L (no) 1997-09-26
KR19980703271A (ko) 1998-10-15
FR06C0014I1 (Direct) 2006-11-17
EA199700267A1 (ru) 1998-04-30
WO1996030010A2 (fr) 1996-10-03
PL183378B1 (pl) 2002-06-28
HU224028B1 (hu) 2005-05-30

Similar Documents

Publication Publication Date Title
NZ304906A (en) Use of fumagillol or a fumagillol ester and an optionally saturated alkylcarboxylic or alkyldicarboxylic acid to fight intestinal infections
BR9405802A (pt) Composição de éster epoxídico
PT871625E (pt) Preparacao de triazoles por adicao organometalica a cetonas e intermediarios destas
PT1066828E (pt) Composicao de aerossol
FI970298A7 (fi) DHA:n käyttö farmaseuttisena koostumuksena
HU9300536D0 (en) Compounds of medical effect
GB9505242D0 (en) Improvements to the patterning of tissue paper
ZA915024B (en) Purification of aqueous liquor
TW414158U (en) Construction of structural body
GB2254612B (en) Conversion of ginkgolide C to ginkgolide B
GB2244055B (en) Resolution of glycidic acid derivatives
DE59404990D1 (de) Fettsäureester von Methylglucosid-Derivaten
PL322002A1 (en) Variants of human dnase i
SI0744399T1 (en) Conversion of substituted 8-chloroquinolines to substituted 8-hydroxyquinolines
GB9009916D0 (en) Preparation of acrylic acid derivatives
PL323148A1 (en) Esters of crabapenemes
EP0728008A4 (en) ADMINISTRATION OF TRACE ELEMENTS TO ANIMALS
AU643825B2 (en) Oxidation of dialkyl polyaromatics to dicarboxypolyaromatics
PL323141A1 (en) Esters of crabapenemes
BR9301967A (pt) Aromatizador de ambientes
IL97544A0 (en) Preparation of penem esters
HU9300076V0 (en) Ball-moving by means of mqgnet to gain points
FI955702A7 (fi) Syklopropaaniestereiden valmistus
GB9103814D0 (en) Improvements relating to sound devices
GB8818710D0 (en) Application of adhesive to elongate members

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
EXPY Patent expired